Abstract
Opioid drugs (e.g., morphine) and opioid combinations (e.g., acetaminophen with codeine or hydrocodone) were the analgesics of choice for the management of both acute and chronic pain in dentistry until the first decade of the twenty-first century. Recently, however, widespread opioid prescribing and the current opioid epidemic have significantly increased governmental scrutiny of healthcare providers who prescribe controlled substances, and it appears that reductions in legitimate opioid prescribing are linked to increases in heroin and illicit fentanyl use. The rationale for using opioids for dental pain was not entirely evidence-based and included the perception that “controlled substances” should be more efficacious than nonaddictive agents. However, concerns over increasing abuse and diversion of opioids, as well as increasingly strong scientific evidence for superior pain relief provided by nonsteroidal anti-inflammatory drugs (NSAIDs), have combined to fundamentally change the contemporary approach to the management of acute dental pain. Benzodiazepines and certain neuromuscular relaxants (e.g., carisoprodol) are also controlled substances with increasing significance as drugs of diversion and abuse. This chapter focuses upon controlled substances used as analgesics, sedatives, and muscle relaxants.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Association of Oral and Maxillofacial Surgeons. White paper: opioid prescribing: acute and postoperative pain management. 2017.
American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with obstructive sleep apnea. Anesthesiology. 2014;120:268–86.
Becker DE. Pharmacokinetic considerations for moderate and deep sedation. Anesth Prog. 2011;58(4):166–73.
Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006;11:126–35.
Dionne RA, Yagiela JA, Cote CJ, et al. Balancing safety and efficacy in the use of oral sedation in dental outpatients. J Am Dent Assoc. 2006;137:502–13.
Ehrich DG, Lundgren JP, Dionne RA, Nicoll BK, Hutter JW. Comparison of triazolam, diazepam and placebo as outpatient oral premedication for endodontic patients. J Endod. 1997;23(3):181–4.
Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;(3):CD002763.
Gordon SM, Shimizu N, Shlash D, Dionne RA. Evidence of safety for individualized dosing of enteral sedation. Gen Dent. 2007;55(5):410–5.
Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics. J Am Dent Assoc. 1999;130:397–407.
Horsfall JT, Sprague JE. The pharmacology and toxicology of the “Holy Trinity”. Basic Clin Pharmacol Toxicol. 2017;120(2):115–9.
Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med. 2018;378(8):693–5.
Maund E, McDaid C, Rice S. Paracetamol and selective and nonselective nonsteroidal anti-inflammatory drugs for the reduction in morphine-related side effects after major surgery: a systematic review. Br J Anaesth. 2011;106:292–7.
McCauley JL, Hyer JM, Ramakrishnan VR, Leite R, Melvin CL, Fillingim RB, Frick C, Brady KT. Dental opioid prescribing and multiple opioid prescriptions among dental patients: administrative data from the South Carolina prescription drug monitoring program. J Am Dent Assoc. 2016;147(7):537–44.
McCauley JL, Leite RS, Gordan VV, Fillingim RB, Gilbert GH, Meyerowitz C, Cochran D, Rinda DB, Brady KT. Opioid prescribing and risk mitigation implementation in the management of acute pain: results from the National Dental Practice-Based Research Network. J Am Dent Assoc. 2018;149(5):353–62.
Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults—an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;(9):CD008659.
Paul G, Parshotam GL, Garg R. Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: diagnostic dilemma. J Anaesthesiol Clin Pharmacol. 2016;32(3):387–8.
Stauble ME, Moore AW, Langman LJ, Boswell MV, Baumgartner R, McGee S, Metry J, Jortani SJ. Hydrocodone in postoperative personalized pain management: pro-drug or drug? Clin Chim Acta. 2014;429:26–9.
Sun C, Hollenbach KA, Cantrell FL. Trends in carisoprodol abuse and misuse after regulatory scheduling: a retrospective review of California poison control calls from 2008 to 2015. Clin Toxicol. 2017;12:1–3.
Vo KT, Horng H, Smollin CG, Benowitz NL. Severe carisoprodol withdrawal after a 14-year addiction and acute overdose. J Emerg Med. 2017;52(5):680–3.
Wie CS. Review of the currently available IV, PO and transdermal opioids. Curr Rev Clin Anesth. 2017;37(170):205–16.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Jeske, A.H. (2019). Opioid Analgesics and Other Controlled Substances. In: Jeske, A. (eds) Contemporary Dental Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-99852-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-99852-7_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99851-0
Online ISBN: 978-3-319-99852-7
eBook Packages: MedicineMedicine (R0)